Insys Therapeutics Announces Retirement of Dr. John N.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
201
Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board

PHOENIX, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ: INSY ) ("Insys" or "the Company") today announced that Dr. John N. Kapoor, its Founder, President and Chief Executive Officer (“CEO”) and Chairman of the Company’s Board of Directors (“Board”) will retire as President and CEO and Chairman effective January 9, 2017.  Dr. Kapoor will remain a member of the Board and will Chair the newly formed Science and Research and Development Committee of the Board. 

In connection with Dr. Kapoor’s retirement, the Board has appointed Dr. Santosh Vetticaden as Interim Chief Executive Officer and Steven Meyer as Chairman of the Board, effective January 9, 2017. 

Dr. Vetticaden joined the Company in April 2015 and currently serves as the Company’s Chief Medical Officer. He has pursued a passion for drug development and commercialization for over 20 years in diverse areas ranging from cardiovascular disease, infectious disease and orphan drug development for hemophilia and pediatric epilepsy. Dr. Vetticaden has previously served as the Chief Medical Officer for multiple public companies and has held leadership positions at Johnson & Johnson, Aventis (now Sanofi), Cubist Pharmaceuticals and has previously served on the board of Amplyx Pharmaceuticals, a private biotech company.  Dr. Vetticaden currently serves on the board of Public Health Foundation Enterprise a non-profit organization devoted to population health.  Dr. Vetticaden received his PhD from the Virginia Commonwealth University, his MD from the University of Maryland and his MBA from the Sloan School of Management at the Massachusetts Institute of Technology.  

Mr. Meyer has served on the Board since November 2010 and currently serves as Chair of the Audit Committee as well as a member of the Compliance Committee. 

In September 2016, the Company previously announced that the Board had commenced a search to identify Dr. Kapoor’s successor as CEO and that process continues.  This CEO search is being conducted by a special committee, comprised of independent Board members, namely Mr. Meyer, Patrick P. Fourteau and Pierre Lapalme.

Dr. Vetticaden stated, “It is an honor to succeed Dr. Kapoor as Interim CEO.  In many ways, Insys is still an R&D company with our corporate efforts primarily focused on developing a promising pipeline of products aimed at benefitting patients in need.  I am encouraged by the progress of our pipeline since joining the Company. I believe that Insys is the world leader in sublingual sprays and with our impressive cannabinoid platform, we have much more to accomplish on the R&D front. On the commercial side, in the short term and once our scheduling is finalized, I look forward to executing on the anticipated launch of SYNDROS™.”

Mr. Meyer stated, “I am confident that Dr. Vetticaden will serve Insys and its stockholders well during this interim period.  I am proud to step into the Chairman role.  The Board is grateful for Dr. Kapoor’s innumerable contributions as Founder, Chairman and CEO.  We wish to honor his desire to retire from his prominent roles in the Company and we are pleased that he will remain a Director and a creative force in our R&D efforts.”

Dr. Kapoor stated, "I stepped into the role of CEO more than a year ago to rebuild the Company from an operational perspective. As I take on a more focused role, I believe Insys is in a better place operationally and positioned to overcome the challenges of the past. I also believe that we have laid out a vision for the Company that gives me great confidence about the future success of Insys and our potential to benefit patients in areas of unmet medical needs."  

About Insys Therapeutics, Inc.

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS ® (fentanyl sublingual spray) but has received approval for the marketing of SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule.  Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with high unmet need.

SUBSYS ®  and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.

Forward-Looking Statements This press release contains forward-looking statements, including statements regarding (i) the belief that Insys is the world leader in sublingual sprays and the national leader in cannabinoid research, (ii) the anticipated scheduling and launch of SYNDROS, (iii) the belief that the Company is operationally in a better place and positioned to overcome the challenges of the past, (iv) the belief that the Company has the potential to benefit patients in areas of unmet medical needs and (v) the belief that SYNDROS has distinct advantages over the current formulation of dronabinol in soft gel capsule. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. For a description of these risks facing the company, please see the risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015 and any subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise these statements, except as may be required by law . 

Contact: Lisa M. Wilson President In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Alley Cat Allies Pushes for Humane Cat Conservation Bill

Updated Category News Views 70

Time to Rethink Conservation: Save the Cats If you’re tuned into the chatter buzzing around the Cayman Islands, you know the clocks are ticking for a decision that could change the approach to handling community cats. Alley Cat Allies is waving the flag, urging the Cayman Islands Parliament to pass a bill that abandons the archaic practice of culling cats by shooting...

Continue Reading
Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 292

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 156

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 136

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Kos & FORTH Partner to Spark Greek Biotech Growth

Updated Category News Views 81

New Frontiers: Greece on the Biotech Map Partnerships in biotech aren't tossed out willy-nilly; they're crafted for precision much like a sculptor shaping marble. Kos Biotechnology Partners and the Foundation for Research and Technology-Hellas (FORTH) are doing exactly that, teaming up to birth a biotechnology incubator on the FORTH campus in Heraklion, Crete. Now tell...

Continue Reading
Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 72

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
Quantum X and Everest Cloud Partner in South Asia Push

Updated Category News Views 108

An Unlikely Alliance for Cutting-Edge Tech You gotta admit, the fusion of a U.S.-based tech outfit with a Nepalese cloud provider wasn't the market move anyone saw coming. But here we are—Quantum X is hitching its quantum computing dreams to Everest Cloud's solid local foothold across six South Asian markets. We're talking Nepal, India, Bangladesh, Bhutan, Sri Lanka,...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 114

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Natural Hydrogen: MAX Power Mining's Vision

Updated Category News Views 184

MAX Power Mining Corp. Driving Innovation in Natural Hydrogen In an era where energy demands are escalating, especially with the rise of artificial intelligence and advanced technologies, the search for sustainable power sources has reached new heights. Enter MAX Power Mining Corp. (OTC: MAXXF) (CSE: MAXX), a trailblazer in the natural hydrogen sector, demonstrating...

Continue Reading
Inland Empire Health Plan Achieves Excellence in GIS Recognition

Updated Category News Views 246

A Celebration of Achievement for Inland Empire Health Plan Inland Empire Health Plan (IEHP) has achieved remarkable recognition by winning its third Special Achievement in GIS (SAG) award from Esri, the global leader in Geographic Information System (GIS) technology. This prestigious accolade highlights IEHP's commitment to utilizing innovative technology to enhance...

Continue Reading
Ryp Labs Triumphs in Lineage’s Global Food Innovation Challenge

Updated Category News Views 226

Ryp Labs Triumphs in Lineage’s Global Food Innovation Challenge In a groundbreaking moment for sustainable food technology, Ryp Labs was announced as the standout winner of Lineage's prestigious innovation challenge aimed at transforming the global food supply chain. The challenge focused on innovative solutions that address pressing issues such as food waste and supply...

Continue Reading
Future Landscape of the UV Stabilizers Market by 2032

Updated Category News Views 176

Growth of the UV Stabilizers Market The UV stabilizers market is gaining momentum, projected to expand from USD 1.4 billion to USD 2.3 billion by 2032, with a compound annual growth rate (CAGR) of 5.5% during the 2024-2032 period. This growth is fueled by the increasing demand for materials that are durable and can endure the degrading effects of ultraviolet (UV)...

Continue Reading
Dr. Rushika Fernandopulle Joins Premera Board of Directors

Updated Category News Views 337

Dr. Rushika Fernandopulle Joins Premera's Board Premera Blue Cross is excited to announce the addition of Dr. Rushika Fernandopulle to its Board of Directors. This decision is part of a strategic effort to strengthen leadership and expertise within the organization. Dr. Fernandopulle takes over from Dr. John Jenrette, who has completed his term this year. Expertise and...

Continue Reading